Heparin-induced thrombocytopenia/thrombosis (HITP) is thought to be mediated by immunoglobulins that activate platelets in the presence of pharmacologic concentrations of heparin, but the molecular basis for this relatively common and often serious complication of heparin therapy has not been established. We found that plasma from each of 12 patients with HITP contained high titer (. 1:200) Invest. 1994. 93:81-88.)
Introduction
Heparin-induced thrombocytopenia (HITP)' associated with thromboembolism was first described more than 30 years ago ( 1, 2) . Hundreds ofcases have since been reported and HITP is now recognized as an important cause ofmorbidity and mortality in patients receiving heparin therapy (3, 4) . HITP differs from most other forms of drug-induced thrombocytopenia in that the responsible antibodies activate platelets in the presence of optimal concentrations of hepanin, rather than merely binding to platelets to promote their destruction (3) (4) (5) . This activation can be blocked in vitro by monoclonal antibodies specific for the platelet Fc receptor (FcyRII) (6) , suggesting that hepann-induced antibodies somehow interact with heparin to form platelet-activating immune complexes. However, attempts to demonstrate such complexes and their binding to intact platelets have yielded negative or equivocal results (3, 7, 8) .
The laboratory diagnosis of HITP is made with tests in which aggregation of platelets is triggered in platelet-rich plasma or release of radiolabeled serotonin from platelets is induced by patient serum in the presence of heparin (3, 4) . Recently, Amiral et al. (9) described an assay for heparin-induced antibodies based on their reaction with immobilized complexes of heparin and platelet factor 4 (PF4), a constituent of platelet alpha granules (9) . In 12 patients who developed thrombocytopenia with or without thrombosis while receiving prophylactic heparin therapy and whose plasma had tested positive in the serotonin release test for heparin-induced antibodies ( 12) were studied. The samples were collected within 2 d of the time heparin was discontinued. 10 were anticoagulated with citrate and 2 with EDTA. The patients, eight women and four men, ranged in age from 51 to 75 yr. Five patients experienced thrombotic symptoms while receiving heparin, including deep vein thrombosis, pulmonary embolism, and jugular vein thrombosis. One patient died from thromboembolic complications. Each plasma sample was adsorbed with ecteola cellulose equilibrated in PBS to remove residual heparin that might be present ( 13) by adding 70 mg ecteola to 1 ml of plasma and incubating for 90 min at 4°C with occasional agitation, and centrifuging at 14,000 g for 1 min. In preliminary studies in which heparin was added to plasma containing heparin-induced antibody, we found that this treatment was capable of removing at least 10 U ofheparin/ml, far more than the amount that might be present after recent heparin therapy. Plasma from patients with other types of thrombocytopenia were obtained from the Platelet Antibody Laboratory of The Blood Center of Southeastern Wisconsin, to which they had been referred for serologic testing.
Isolation ofplatelets. Platelets were isolated from freshly collected blood anticoagulated with acid citrate dextrose sufficient to produce a pH of 6.5 and were washed three times in RCD buffer, pH 6.5, containing 50 ng/ml PGE,. The washed platelets were nonactivated by the criterion that their mean fluorescence intensity in flow cytometry after incubation with fluorescein-labeled monoclonal antibody S12 specific for P-selectin was not significantly different from that ofplatelets incubated with equal amounts of fluorescein-labeled normal mouse IgG. A marked increase in S 12 binding occurred when platelets were activated by the TI short peptide of the platelet thrombin receptor.
Purification of PF4. PF4 was purified according to Medici et al. (14) , with minor modifications. 10 U of platelets < 1 d old from randomly chosen whole blood donors was pooled and centrifuged at 400 g for 10 min to remove red cells. The platelet-rich plasma was pelleted at 1,200 g, washed three times in RCD buffer, pH 6.5, containing EDTA 0.002 M, and resuspended in PBS containing 0.00 1 M CaC12, and 0.00 14 M PMSF in dimethylsulfoxide at a concentration of 1010 platelets/ ml in a total volume of 50 ml. Platelet release was induced with TI short peptide ( 10, 11 ) at a final concentration of 5 MM for 20 min at 37°C with occasional shaking. The activated platelets were then pelleted at 3,000 g for 30 min at 4°C. Ammonium sulfate was added to the supernatant at 50% saturation and the mixture was incubated at 4°C overnight. The precipitate was discarded and the final supernatant was dialyzed exhaustively against PBS at 4°C. The dialyzed supernatant ( 250 ml) was then incubated with 20 ml of packed heparin-Agarose beads for 4 h at 4VC with gentle stirring. The beads were washed sequentially with 3 vol each of 0.145 M PB-NaCl, 0.8 M PB-NaCl (to remove f3-thromboglobulin and thrombospondin) and resuspended in Binding of IgG and 1gMA to HUVEC. HUVEC were isolated from human umbilical vein cords by collagenase digestion and cultured ( 17, 18) . The cells were grown to subconfluency (85-95% confluent) in T75 flasks (Corning) in RPMI 1640 (Celox, Hopkins, MN) supplemented with 15% horse serum, 100 Aig/ml endothelial cell growth supplement (Collaborative Research Inc., Lexington, MA), and 100 mg/ ml heparin (from porcine intestinal mucosa; Sigma Chemical Co., St. Louis, MO), 100 U/ml penicillin, and 100 jg/ml streptomycin. Cell cultures were incubated at 370C in a water-saturated atmosphere of 95% air, 5% CO2, and were used between the second and the fourth passage. For flow cytometric studies, endothelial cells were detached from the tissue culture plate with PBS, 10% FCS containing 10 mM of EDTA, and washed twice with PBS-10% FBS. 5 X I0 5 cells were resuspended in PBS, FCS, NaN3 (0.02%) and were treated with patient plasma in the presence and absence of PF4 and heparin as described in Results. Bound IgG and IgM were assayed as described above for platelets, except that a linear rather than a logarithmic scale was used to evaluate forward scatter.
Results
Determination of the optimum heparin/PF4 ratio for formation of complexes recognized by heparin-induced antibodies. Complexes formed in mixtures containing heparin (lot 1) in concentrations ranging from 0.01 to 0.5 U/ml and purified PF4 at concentrations ranging from 5 to 50,gg/ml were immobilized (see Methods) in triplicate in the wells of a polystyrene microtiter plate and used as targets for heparin-induced antibodies. Results obtained with the plasma ofpatient 1 are shown in Fig. 1 A. IgG bound readily to complexes formed in mixtures of 0.05 U/ml heparin and 10 g/ml PF4 or 0.1 U/ml heparin and 25 jig/ml PF4. However, at a given concentration ofheparin, doubling of the PF4 concentration or reducing it by 50% led to complete loss or a marked reduction of reactivity. When these studies were repeated with fresh heparin from the same manufacturer (lot 2), complexes optimal for IgG binding were formed at higher heparin/PF4 ratios, e.g., 0.3 U/ml heparin and 10 Aig/ml PF4, or 1.0 U/ml heparin and 25 ,ug/ml PF4 (Fig. 1 B) . With complexes formed at greater concentrations of heparin, IgG binding diminished to an OD of -0.40, but remained above background even with a ratio of 10 U/ml heparin per 10 ,ug/ml PF4. The basis for the variable behavior of different lots of heparin was examined by studying vials of heparin ofdifferent ages. Each oftwo vials of fresh heparin (lot 2) and six of nine vials that were several months postoutdate (lot 1) produced a pattern similar to that shown in Fig. 1 B, whereas three of nine outdated vials produced the pattern shown in Fig. 1 A. The anticoagulant activities of heparins from lots 1 and 2 were indistinguishable, as measured by their abilities to prolong the partial thromboplastin time of normal plasma (data not shown). Both in-date (expiration 1996) and outdated ( 1991 ) heparin from the other two manufacturers (Lyphomed and Upjohn) yielded patterns similar to those shown in Fig. 1 B. Regardless ofthe lot ofheparin used, binding of IgG to heparin/PF4 complexes was abolished when heparin at a concentration of 1.0 U/ml was added to plasma before it was incubated with the immobilized complexes (data not shown). Results similar to those shown for patient 1 in Fig. 1 (Fig. 2 A) . Three plasmas (nos. 3, 5, and 9) also reacted with PF4 alone, but less strongly than with the complexes. In each case, binding of IgG to heparin/PF4 complexes was reduced to the level obtained with immobilized PF4 alone by adding heparin to the wells at a concentration of 0.15 U/ml before the addition ofplasma (Fig. 2 A) . This concentration of heparin had no effect on the binding of four quinine-or quinidine-induced platelet antibodies or four antibodies specific for the P1 Al alloantigen to immobilized GPIIb/IIIa complex ( 16), and did not appear to remove immobilized PF4 from the wells since the binding of goat antibody specific for human PF4 was unaffected (data not shown). As shown in Fig. 2 Heparin-induced IgG and IgM antibodies bind to cultured HUVEC in the presence ofPF4 alone. Suspensions of 5 X IO' HUVEC were incubated with 50 ,ul of patient plasma diluted 1:10 in PBS containing 10 ,tg/ml PF4 for 60 min at 4°C. After washing three times, bound IgG and IgM were determined by flow cytometry. As illustrated in Fig. 4 for patient 2, significant quantities of IgG were deposited on endothelial cells in the presence (Fig. 4 C) but not in the absence (Fig. 4 A) of PF4. The IgG binding was abolished when 0.05 U/ml heparin (lot 1) was added to the plasma/PF4 mixture before incubation with HUVEC (Fig. 4 D) and did not occur with plasma containing heparin alone (0.05 U/ml) (Fig. 4 B) . Similar binding Each of the five plasmas shown to contain IgM antibodies reactive with heparin/PF4 complexes by ELISA (2, 3, and 5-7) also exhibited IgM binding to HUVEC in the presence of PF4 (shown for patient 2 in Fig. 4 E) but not in the absence of PF4. Mean fluorescence intensity of IgM binding to HUVEC incubated with plasma ofthese five patients ranged from 2.1 to 5.0 (average, 3.22) times control. With 10 normal plasmas and with plasma from the other 7 patients, this ratio was always < 1.5. Binding of IgG and 1gM to HUVEC in the presence of PF4 was unaffected by pretreatment of the target cells with the Fc-yRII-specific monoclonal antibody IV.3 at 10,ug/ml. HUVEC incubated with 10 Ag/ml PF4 and then washed also bound IgG from subsequently added patient plasma, but not normal plasma (data not shown). This binding was abolished by treating the PF4-treated HUVEC with 0.05 U/ml heparin (lot 1) before adding patient plasma. In these studies, binding of PF4 to HUVEC was demonstrated by incubating the PF4-treated cells with goat anti-PF4, followed by DTAF-labeled donkey anti-goat IgG and analysis by flow cytometry (data not shown). When the PF4-coated cells were incubated with 0.05 U/ml heparin before analysis, no binding of anti-PF4 antibody was observed.
Discussion
These findings indicate that platelet-activating, heparin-induced antibodies are specific for PF4/heparin complexes and can be detected in a microtiter plate assay using immobilized complexes as targets, in confirmation of Amiral et al. (9) . Amiral et al. used a ratio of 0.15 U/ml heparin per 20 ,g/ml recombinant PF4 in their studies without specifying why these quantities were chosen. We found that with fresh heparin (lot 2), and with six ofnine vials ofheparin several months postoutdate (lot 1), target complexes formed at a ratio of -0.3 U/ml heparin per 10 ,ug/ml PF4 were most effective in antibody binding (Fig. 1 B) . With three of nine vials of outdated heparin, a ratio of 0.05 U/ml heparin per 10,ug/ml PF4, similar to the ratio used by Amiral et al. (9) , was optimal (Fig. 1 A) . It is apparent from Fig. 1 that with either lot of heparin, the ratio of heparin / PF4 used to form target complexes is important, especially with vials yielding the pattern shown in Fig. 1 A. The molecular mass of the human PF4 tetramer is -32,000 daltons (19, 20) . The PF4 gene has been cloned and sequenced (21, 22) and the structure of the PF4 tetramer has been partially characterized (20, 23, 24) . Heparin is thought to bind to lysine-rich domains carried on alpha-helical structures near the COOH terminus of each PF4 monomer (20, 24, 25) . Assuming a specific activity of heparin of 174 U/mg (see Methods) and an average molecular mass of 12,000 daltons for pharmaceutical heparin (25, 26) , the molar ratio of heparin/ PF4 required for optimum complex formation with fresh heparin (lot 2) can be calculated to be -1:2. With the older lots of heparin yielding the pattern shown in Fig. 1 A, (Fig. 2  B) . To our knowledge, only one example of a possible heparininduced IgM antibody has been described previously (28) . The weak binding of antibodies from three patients to PF4 alone (Fig. 2 A) is currently unexplained, but is consistent with the possibility that some individuals produce PF4-specific antibodies together with those that recognize heparin/PF4 complexes. The sensitivity of the microtiter tray ELISA was remarkable, in that each of 12 plasmas containing heparin-induced antibodies gave positive reactions at a dilution of 1:200 and 9 were positive at 1:500, whereas the serotonin release test was positive at a dilution of 1:100 with only 2 (Table I) . It is generally agreed that serotonin release is more sensitive than the commonly used platelet aggregation test (3, 11, 29) . Further studies are required to characterize fully the specificity of the ELISA for the diagnosis of HITP. At a plasma dilution of 1:200, all 12 HITP plasmas were positive for IgG binding, whereas 18 normal plasmas and 50 plasmas from patients with other types of immune thrombocytopenia were negative at 1:50. However, 3 of the 50 patient plasmas were positive for IgG at 1:10. Plasma from the same three patients contained stronger ( 1:50) IgM antibodies reactive with heparin/PF4 complexes in ELISA. It is not currently known whether any of these individuals were previously exposed to heparin. At a dilution of 1:100, only plasma from patients with HITP gave positive reactions for IgM. Studies are in progress to optimize the ELISA for sensitivity and specificity and to define further the clinical significance of positive reactions. It will be of great interest to learn whether IgM antibodies, which may not be capable of causing thrombocytopenia (see discussion to follow), signal a primary immune response in patients at risk to develop HITP and thrombosis.
In the presence of PF4 and heparin at an optimum ratio, (31 ) .
Human endothelial cells express proteoglycan molecules consisting of a protein core to which is attached sulfated oligosaccharides with heparin-like properties (32) . Only a small fraction of these molecules regulate the activity of antithrombin III, but all probably react with PF4 (32) . Binding of PF4 to endothelial cell proteoglycans (33, 34) is thought to account for its rapid clearance from the circulation after intravenous injection (35) (36) (37) . Our studies demonstrate that binding of PF4 to HUVEC creates a target for heparin-induced IgG and IgM immunoglobulins (Fig. 4) . Cines et al. (38) described the binding of heparin-induced antibodies to HUVEC monolayers in the absence of added PF4 and concluded that the antibodies are specific for heparan sulfate on the cell surface, but these findings were not reproduced by another group (39) . None of the 12 plasma samples that we studied deposited IgG or IgM on HUVEC in the absence of added PF4. In their studies, Cines et al. (35) used 50% serum that had been absorbed to remove heparin, but may have contained significant amounts of PF4 released from platelets in the clotting process. Platelets in 1 ml of normal blood contain -6 ,g PF4 (20, 37) , and its release in the clotting process could produce a serum PF4 level in the range of 10 ,g/ml, about the concentration we found optimal to promote binding of antibody to HUVEC. Even in a thrombocytopenic patient, significant quantities of PF4 are likely to be present in serum. It seems possible that the findings ofCines et al., can be explained by PF4 contributed by serum to their reaction mixtures.
On the basis ofthese findings, it is possible to propose a new model for the pathogenesis of heparin-induced thrombocytopenia and thrombosis. Under normal conditions, only minute quantities (-3 ng/ml) of PF4 are found in human plasma (37) . However, significant amounts of PF4 are normally associated with endothelial cell proteoglycans (32) . After intravenous injection of heparin, the plasma level of PF4 increases 1 5-30-fold and remains elevated for several hours, apparently because PF4 is mobilized by the injected heparin from endothelial cells (35) (36) (37) Further studies will be required to test the validity of this model and its implications for the diagnosis and treatment of heparin-induced thrombocytopenia/thrombosis. Our findings provide added support for the use of inhibitors ofplatelet function in the treatment of patients with HITP. The demonstration that antibody binds only to heparin/PF4 complexes formed at certain ratios of heparin / PF4 suggests the possibility that in vitro studies may lead to the identification ofagents that act therapeutically by disrupting or preventing the formation of complexes capable of binding antibody.
